354 related articles for article (PubMed ID: 11446884)
1. Efficacy of treatment with chimeric monoclonal antibody (Infliximab) to tumor necrosis factor-alpha for Crohn's disease in Japan: evaluation by rapid turnover proteins, and radiologic and endoscopic findings.
Asakura H; Yao T; Matsui T; Koganei K; Fukushima T; Takazoe M; Hobara R; Nakano H; Okamura S; Matsueda K; Kashida H; Makiyama K; Hiwatashi N; Kashiwagi K; Hibi T
J Gastroenterol Hepatol; 2001 Jul; 16(7):763-9. PubMed ID: 11446884
[TBL] [Abstract][Full Text] [Related]
2. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S
Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
[TBL] [Abstract][Full Text] [Related]
3. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial.
D'haens G; Van Deventer S; Van Hogezand R; Chalmers D; Kothe C; Baert F; Braakman T; Schaible T; Geboes K; Rutgeerts P
Gastroenterology; 1999 May; 116(5):1029-34. PubMed ID: 10220494
[TBL] [Abstract][Full Text] [Related]
4. Prediction of antitumour necrosis factor clinical efficacy by real-time visualisation of apoptosis in patients with Crohn's disease.
Van den Brande JM; Koehler TC; Zelinkova Z; Bennink RJ; te Velde AA; ten Cate FJ; van Deventer SJ; Peppelenbosch MP; Hommes DW
Gut; 2007 Apr; 56(4):509-17. PubMed ID: 17082252
[TBL] [Abstract][Full Text] [Related]
5. Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis.
Keating GM; Perry CM
BioDrugs; 2002; 16(2):111-48. PubMed ID: 11985485
[TBL] [Abstract][Full Text] [Related]
6. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease.
Kugathasan S; Werlin SL; Martinez A; Rivera MT; Heikenen JB; Binion DG
Am J Gastroenterol; 2000 Nov; 95(11):3189-94. PubMed ID: 11095340
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of repeated infliximab infusions for Crohn's disease: 1-year clinical experience.
Cohen RD
Inflamm Bowel Dis; 2001 May; 7 Suppl 1():S17-22. PubMed ID: 11380038
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.
Rutgeerts P; D'Haens G; Targan S; Vasiliauskas E; Hanauer SB; Present DH; Mayer L; Van Hogezand RA; Braakman T; DeWoody KL; Schaible TF; Van Deventer SJ
Gastroenterology; 1999 Oct; 117(4):761-9. PubMed ID: 10500056
[TBL] [Abstract][Full Text] [Related]
9. CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial.
Sandborn WJ; Feagan BG; Radford-Smith G; Kovacs A; Enns R; Innes A; Patel J
Gut; 2004 Oct; 53(10):1485-93. PubMed ID: 15361500
[TBL] [Abstract][Full Text] [Related]
10. Monitoring functional serum antitumor necrosis factor antibody level in Crohn's disease patients who maintained and those who lost response to anti-TNF.
Yamada A; Sono K; Hosoe N; Takada N; Suzuki Y
Inflamm Bowel Dis; 2010 Nov; 16(11):1898-904. PubMed ID: 20310016
[TBL] [Abstract][Full Text] [Related]
11. Use of infliximab in the treatment of Crohn's disease in children and adolescents.
Hyams JS; Markowitz J; Wyllie R
J Pediatr; 2000 Aug; 137(2):192-6. PubMed ID: 10931411
[TBL] [Abstract][Full Text] [Related]
12. Early Australian experience with infliximab, a chimeric antibody against tumour necrosis factor-alpha, in the treatment of Crohn's disease: is its efficacy augmented by steroid-sparing immunosuppressive therapy? The Infliximab User Group.
Mortimore M; Gibson PR; Selby WS; Radford-Smith GL; Florin TH;
Intern Med J; 2001 Apr; 31(3):146-50. PubMed ID: 11478343
[TBL] [Abstract][Full Text] [Related]
13. [Infliximab in the treatment of patients with Crohn's disease: preliminary report].
Gellona V J; Zarraonandia A A; Zúñiga D A; Palma C R; Contreras P J; Silva Ch J; González D R; Quintana V C
Rev Med Chil; 2006 Mar; 134(3):320-5. PubMed ID: 16676104
[TBL] [Abstract][Full Text] [Related]
14. Treatment of perianal fistulas in Crohn's disease by local injection of antibody to TNF-alpha accounts for a favourable clinical response in selected cases: a pilot study.
Asteria CR; Ficari F; Bagnoli S; Milla M; Tonelli F
Scand J Gastroenterol; 2006 Sep; 41(9):1064-72. PubMed ID: 16938720
[TBL] [Abstract][Full Text] [Related]
15. Review article: efficacy of infliximab in Crohn's disease--induction and maintenance of remission.
Rutgeerts PJ
Aliment Pharmacol Ther; 1999 Sep; 13 Suppl 4():9-15; discussion 38. PubMed ID: 10597334
[TBL] [Abstract][Full Text] [Related]
16. High serum tumor necrosis factor-alpha levels are associated with lack of response to infliximab in fistulizing Crohn's disease.
Martínez-Borra J; López-Larrea C; González S; Fuentes D; Dieguez A; Deschamps EM; Pérez-Pariente JM; López-Vázquez A; de Francisco R; Rodrigo L
Am J Gastroenterol; 2002 Sep; 97(9):2350-6. PubMed ID: 12358255
[TBL] [Abstract][Full Text] [Related]
17. Tumor necrosis factor-alpha antibody for induction of remission in Crohn's disease.
Akobeng AK; Zachos M
Cochrane Database Syst Rev; 2004; 2003(1):CD003574. PubMed ID: 14974022
[TBL] [Abstract][Full Text] [Related]
18. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease.
Sandborn WJ; Hanauer S; Loftus EV; Tremaine WJ; Kane S; Cohen R; Hanson K; Johnson T; Schmitt D; Jeche R
Am J Gastroenterol; 2004 Oct; 99(10):1984-9. PubMed ID: 15447761
[TBL] [Abstract][Full Text] [Related]
19. [Anti-TNF antibodies in the treatment of inflammatory intestinal stenoses in Crohn's disease].
Holtmann M; Wanitschke R; Helisch A; Bartenstein P; Galle PR; Neurath M
Z Gastroenterol; 2003 Jan; 41(1):11-7. PubMed ID: 12541166
[TBL] [Abstract][Full Text] [Related]
20. Basic fibroblast growth factor as a response parameter to infliximab in fistulizing Crohn's disease.
Gao Q; Hogezand RA; Lamers CB; Verspaget HW
Aliment Pharmacol Ther; 2004 Sep; 20(5):585-92. PubMed ID: 15339330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
